Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Accumulated Expenses (2020 - 2024)

Immuneering has reported Accumulated Expenses over the past 5 years, most recently at $4.6 million for Q3 2024.

  • Quarterly results put Accumulated Expenses at $4.6 million for Q3 2024, up 39.22% from a year ago — trailing twelve months through Sep 2024 was $4.6 million (up 39.22% YoY), and the annual figure for FY2023 was $5.2 million, up 14.95%.
  • Accumulated Expenses for Q3 2024 was $4.6 million at Immuneering, up from $3.8 million in the prior quarter.
  • Over the last five years, Accumulated Expenses for IMRX hit a ceiling of $5.2 million in Q4 2023 and a floor of $85792.0 in Q1 2022.
  • Median Accumulated Expenses over the past 5 years was $2.4 million (2023), compared with a mean of $2.6 million.
  • Biggest five-year swings in Accumulated Expenses: tumbled 92.06% in 2022 and later surged 2711.93% in 2023.
  • Immuneering's Accumulated Expenses stood at $698992.0 in 2020, then surged by 317.36% to $2.9 million in 2021, then skyrocketed by 54.29% to $4.5 million in 2022, then increased by 14.95% to $5.2 million in 2023, then dropped by 11.23% to $4.6 million in 2024.
  • The last three reported values for Accumulated Expenses were $4.6 million (Q3 2024), $3.8 million (Q2 2024), and $2.6 million (Q1 2024) per Business Quant data.